Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Background.The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors.Case.A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented.Conclusion.Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.